… forms of ABL and SRC resemble one another, we tested two dual SRC-ABL kinase inhibitors,
AP23464 and PD166326, against 58 imatinib-resistant (IM R ) BCR/ABL kinase variants. …

… inhibitors are smaller than imatinib, contact fewer residues, and require fewer Abl … Src/Abl
inhibitors should inhibit most imatinib-resistant mutants and showed previously that two Src/Abl …

… Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly
inhibit Bcr-Abl … In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the …

… For example, the constitutively activated Bcr/abl kinase, a mutant form of Abl, a nonreceptor
… that Src inhibitors could circumvent cytotoxic drug resistance stemming from increased drug …

… AZD0530 monotherapy initially retarded xenograft growth, but drug resistance rapidly
emerged, while the combined regimen anastrozole/AZD0530 reduced drug resistance and …

… c-Src is one of the target molecules for anti-cancer kinase inhibitors, yet the precise mechanism
by which c-Src confers drug resistance … cell-edge translocation of c-Abl, we proposed that …

… Mechanistically, bosutinib effectively decreased the activity of Src/Abl and PI3K/AKT/mTOR, …
that Src and c-Abl are potential therapeutic targets in NB and that the novel Src/Abl inhibitor …

… In summary, our results reveal that Src and Abl are potential therapeutic targets in ESCC …
drug like doxorubicin (Dox). Taken together, our results suggest that Src and Abl are potential …

… kinase [21], dasatinib is predicted to bind to the active conformation, which is more structurally
conserved between ABL and SRC kinases than is the inactive conformation [21]. This …

… Src is increased in hematopoietic cells expressing Bcr-Abl … classical Bcr-Abl inhibitors, various
dual Src/Abl inhibitors have … and delaying the onset of acquired drug resistance [123, 94]. …